• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5069800)   Today's Articles (40)
For: Paassen PV, Pittrow D, Scheidegger C, Klotsche J, Ellerbroek PM. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients. Immunotherapy 2020;12:131-139. [PMID: 32066296 DOI: 10.2217/imt-2019-0175] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]  Open
Number Cited by Other Article(s)
1
Guo J, Weng J, Zhou F, Gu X. An industry perspective on hyaluronidase co-formulated biopharmaceutics. J Control Release 2025;381:113573. [PMID: 40010413 DOI: 10.1016/j.jconrel.2025.02.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2024] [Revised: 02/19/2025] [Accepted: 02/23/2025] [Indexed: 02/28/2025]
2
Duff K, Soresini A, Wolf N, Altan Ş, Bencomo W, Fairchild A, Ivankovic I, Sarpong E, Kuczkowska A. Individualized Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administration in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Nurse's Role. JOURNAL OF INFUSION NURSING 2025;48:166-180. [PMID: 40072841 DOI: 10.1097/nan.0000000000000581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/14/2025]
3
Dimou M, Vacca A, Sánchez-Ramón S, Karakulska-Prystupiuk E, Lionikaite V, Siffel C, Anderson-Smits C, Kamieniak M. Real-World Effectiveness, Safety, and Tolerability of Facilitated Subcutaneous Immunoglobulin 10% in Secondary Immunodeficiency Disease: A Systematic Literature Review. J Clin Med 2025;14:1203. [PMID: 40004732 PMCID: PMC11856383 DOI: 10.3390/jcm14041203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2024] [Revised: 01/28/2025] [Accepted: 02/05/2025] [Indexed: 02/27/2025]  Open
4
Lefèvre G, Borget I, Lefèvre C, Maherzi C, Nucit A, Hennaoui M, Schmidt A, Lennon H, Grenier B, Daydé F, Mahlaoui N. Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France. PLoS One 2025;20:e0313694. [PMID: 39854356 PMCID: PMC11759344 DOI: 10.1371/journal.pone.0313694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Accepted: 10/29/2024] [Indexed: 01/26/2025]  Open
5
Mathias N, Huille S, Picci M, Mahoney RP, Pettis RJ, Case B, Helk B, Kang D, Shah R, Ma J, Bhattacharya D, Krishnamachari Y, Doucet D, Maksimovikj N, Babaee S, Garidel P, Esfandiary R, Gandhi R. Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design. Adv Drug Deliv Rev 2024;209:115301. [PMID: 38570141 DOI: 10.1016/j.addr.2024.115301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 03/21/2024] [Accepted: 03/28/2024] [Indexed: 04/05/2024]
6
Ar MC, El Fakih R, Gabbassova S, Alhuraiji A, Nasr F, Alsaeed A, Sayinalp N, Marashi M. Management of humoral secondary immunodeficiency in hematological malignancies and following hematopoietic stem cell transplantation: Regional perspectives. Leuk Res 2023;133:107365. [PMID: 37643508 DOI: 10.1016/j.leukres.2023.107365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 07/17/2023] [Accepted: 07/25/2023] [Indexed: 08/31/2023]
7
Borte M, Hanitsch LG, Mahlaoui N, Fasshauer M, Huscher D, Speletas M, Dimou M, Kamieniak M, Hermann C, Pittrow D, Milito C. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study. J Clin Immunol 2023:10.1007/s10875-023-01470-2. [PMID: 37036560 PMCID: PMC10088636 DOI: 10.1007/s10875-023-01470-2] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Accepted: 03/08/2023] [Indexed: 04/11/2023]
8
Knowles SP, Printz MA, Kang DW, LaBarre MJ, Tannenbaum RP. Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery. Expert Opin Drug Deliv 2021;18:1673-1685. [PMID: 34585991 DOI: 10.1080/17425247.2021.1981286] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
9
Gremski LH, Matsubara FH, da Justa HC, Schemczssen-Graeff Z, Baldissera AB, Schluga PHDC, Leite IDO, Boia-Ferreira M, Wille ACM, Senff-Ribeiro A, Veiga SS. Brown spider venom toxins: what are the functions of astacins, serine proteases, hyaluronidases, allergens, TCTP, serpins and knottins? J Venom Anim Toxins Incl Trop Dis 2021;27:e20200188. [PMID: 34377142 PMCID: PMC8314928 DOI: 10.1590/1678-9199-jvatitd-2020-0188] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2021] [Accepted: 03/09/2021] [Indexed: 12/27/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA